GlassScriptPhysician profile
Stanley H Appel
NPI 1124009113
$27,733.71
in general payments reported to CMS, 2019-2025
28 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $291 · 2021: $397 · 2022: $11K · 2023: $12K · 2024: $366 · 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,550.00 |
| Food and Beverage | $1,351.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $12,660.12 | 2019-2025 | Radicava |
| Ucb Sa | $10,500.00 | 2023 | |
| Glaxosmithkline, LLC. | $1,950.00 | 2025 | |
| Amylyx Pharmaceuticals, INC. | $652.75 | 2023-2024 | Relyvrio |
| Avanir Pharmaceuticals, INC. | $633.58 | 2019-2022 | |
| Biogen, INC. | $326.42 | 2022-2024 | Qalsody |
| Csl Behring | $244.97 | 2019-2022 | |
| Allergan, INC. | $89.97 | 2019-2020 | |
| Genzyme Corporation | $84.31 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $73.06 | 2023-2024 | Nuedexta |
| Amgen INC. | $71.43 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $61.82 | 2021 | |
| Merz North America, INC. | $44.46 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $43.19 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $42.20 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $38.29 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $33.06 | 2020 | |
| Pfizer INC. | $30.70 | 2019-2022 | |
| Ge Healthcare | $22.81 | 2019 | |
| Acorda Therapeutics, INC | $22.39 | 2019 | |
| Abbvie INC. | $19.21 | 2025 | |
| Alnylam Pharmaceuticals INC. | $17.17 | 2020 | |
| Strongbridge US INC. | $17.10 | 2020 | |
| Shire North American Group INC | $16.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.40 | 2022 | |
| Lundbeck LLC | $11.99 | 2021 | |
| Merck Sharp & Dohme LLC | $11.80 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Appel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.